AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for April 22, 2014 meeting (Tab 1; pages 3-6)

IV. Secretary’s report (Tab 2; pages 7-8)

V. Old Business (Tab 3; pages 9-14)
   A. HMO (UHC) response to DURB follow-up questions regarding “directed interventions”
   B. Summary of Patients on Chronic Opioids Dose with Acute Diagnosis
   C. Current direct-acting antiviral Hepatitis C drugs by genotype

VI. New Business
   A. Paliperidone palmitate (Invega Trinza®) proposed protocol (Tab 4; pages 15-16)
   B. Protocols review (Tab 5; pages 17-26)
      1. Novel oral anticoagulants
      2. Testosterone products

VII. Informational Highlights/Reports
   2. Summary of DURB Action Items (Tab 7; pages 29-30)
   3. DHS and DHSS Programs Top Drugs Report (Tab 8; pages 31-50)
   4. Medication information: (Tab 9; pages 51-55)
      (a) Heroin Use Surges Among Whites Who Abuse Prescription Painkillers
      (b) Injectable Testosterone Tied to Higher MI, Stroke Risk Than Gels
      (c) FDA approves first 3-month schizophrenia treatment
      (d) The FDA warns on newer class of type 2 diabetes drugs (SGLT2 inhibitors)